Abstract
No pharmacological intervention has been shown convincingly to improve neurological outcome in stroke patients after the brain tissue is infarcted. While conventional therapeutic strategies focus on preventing brain damage, stem cell treatment has the potential to repair the injured brain tissue. Stem cells not only produce a source of trophic molecules to minimize brain damage caused by ischaemia/reperfusion and promote recovery, but also potentially turn to new cells to replace those lost in ischaemic core. Although preclinical studies have shown promise, stem cell therapy for stroke treatment in human is still at an early stage and it is difficult to draw conclusions from current clinical trials about the efficacy of the different treatments used in humans. This article reviews the potential of various types of stem cells, from embryonic to adult to induced pluripotent stem cells, in stroke therapy, highlights new evidence from the ongoing clinical trials and discusses some of the problems associated with translating stem cell technology to a clinical therapy for stroke.
Keywords: Stroke, stem cells, endogenous, exogenous, pre-clinical studies, clinical trials.
CNS & Neurological Disorders - Drug Targets
Title:Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
Volume: 12 Issue: 2
Author(s): Joyce S. Balami, Rosemary A. Fricker and Ruoli Chen
Affiliation:
Keywords: Stroke, stem cells, endogenous, exogenous, pre-clinical studies, clinical trials.
Abstract: No pharmacological intervention has been shown convincingly to improve neurological outcome in stroke patients after the brain tissue is infarcted. While conventional therapeutic strategies focus on preventing brain damage, stem cell treatment has the potential to repair the injured brain tissue. Stem cells not only produce a source of trophic molecules to minimize brain damage caused by ischaemia/reperfusion and promote recovery, but also potentially turn to new cells to replace those lost in ischaemic core. Although preclinical studies have shown promise, stem cell therapy for stroke treatment in human is still at an early stage and it is difficult to draw conclusions from current clinical trials about the efficacy of the different treatments used in humans. This article reviews the potential of various types of stem cells, from embryonic to adult to induced pluripotent stem cells, in stroke therapy, highlights new evidence from the ongoing clinical trials and discusses some of the problems associated with translating stem cell technology to a clinical therapy for stroke.
Export Options
About this article
Cite this article as:
Balami Joyce S., Fricker Rosemary A. and Chen Ruoli, Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment, CNS & Neurological Disorders - Drug Targets 2013; 12 (2) . https://dx.doi.org/10.2174/1871527311312020007
DOI https://dx.doi.org/10.2174/1871527311312020007 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Location of Vascular Flap is Related with Daily Activity Patterns in Non-traumatic Acute Aortic Syndrome in a Chinese Population
Current Signal Transduction Therapy Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Current Pharmaceutical Design N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain
Current Pharmaceutical Design Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Current Vascular Pharmacology Endothelial Lipase: A Key Player in HDL Metabolism Modulates Inflammation and Atherosclerotic Risk
Mini-Reviews in Medicinal Chemistry HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling
Current Medicinal Chemistry Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Current Vascular Pharmacology The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Cardioprotective Role of <i>Theobroma cacao</i> against Isoproterenol-Induced Acute Myocardial Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Left Ventricular 2-[<sup>18</sup>F]-Fluoro-2-Deoxy-D-Glucose Uptake Using Modified Oral Glucose Loading Protocol With Pre-Medicated Niacin On Positron Emission Tomography/Computed Tomography - A Preliminary Study
Current Molecular Imaging (Discontinued) Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features
Current Cardiology Reviews Helicobacter pylori Eradication Improves the Malnutrition, Inflammation and Atherosclerosis Syndrome in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Are Topological Properties of Drug Targets Based on Protein-Protein Interaction Network Ready to Predict Potential Drug Targets?
Combinatorial Chemistry & High Throughput Screening Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Risk Scores for Patients with Chest Pain: Evaluation in the Emergency Department
Current Cardiology Reviews Comparison Between the Effects of Bupivacaine and Levobupivacaine for Spinal Anesthesia on QT Dispersion
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot Topic: Natural Products for the Healthy Heart (Guest Editor : Dipak K. Das)]
Current Pharmaceutical Biotechnology